TokenPost·

Retension Pharmaceuticals Posts $7.33 Q3 GAAP Loss Per Share

Your call?

Cash and cash equivalents totaled $9.2 million at Sept. 30, excluding about $45.1 million in net IPO proceeds from a deal that closed after the quarter.

Share

More news